HIGD2B

Across TCGA pan-cancer cohorts, HIGD2B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of HIGD2B’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where HIGD2B RNA is repressed in tumor relative to normal tissue. In most cancer types HIGD2B is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, BRCA, and BLCA are the cancer types where HIGD2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HIGD2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−0.347	<.001	11	view →
BRCA	Female	II,III,IV	+0.074	<.001	6	view →
BLCA	Male	All	+0.167	.041	4	view →
KICH	All	All	−0.145	<.001	4	view →
LUAD	All	II,III,IV	+0.078	.007	4	view →
KIRC	Male	All	−0.051	.005	4	view →
PAAD	Female	All	−0.090	.046	2	view →
PRAD	All	All	+0.052	.030	2	view →
COAD	All	All	+0.051	.027	2	view →
LIHC	Male	All	+0.050	.008	2	view →
LUSC	All	All	+0.048	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

HIGD2B–THCA

Open the THCA breakdown →